Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S(c)TIL
- Development stage
- Phase 2
- Lead developer
- Beijing Chineo Medical Technology
- Modality
- Cell Therapies, Gene Therapies
01
Overview
S(c)TIL is a gene-modified tumor-infiltrating lymphocyte (TIL) cell therapy. It is currently under clinical investigation for the treatment of gynecological malignancies and advanced malignant solid tumors. Developed by Beijing ChineoMedical Technology Co., Ltd, this therapy involves genetically modifying a patient's own tumor-infiltrating lymphocytes to enhance their ability to recognize and eliminate cancer cells, often administered in combination with PD-1 monoclonal antibodies.
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on S(c)TIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S(c)TIL.